Cherrington J - Search Results

1

Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling.

Itokawa T, Nokihara H, Nishioka Y, Sone S, Iwamoto Y, Yamada Y, Cherrington J, McMahon G, Shibuya M, Kuwano M, Ono M. Itokawa T, et al. Among authors: cherrington j. Mol Cancer Ther. 2002 Mar;1(5):295-302. Mol Cancer Ther. 2002. PMID: 12489845

2

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.

Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA. Liao AT, et al. Blood. 2002 Jul 15;100(2):585-93. doi: 10.1182/blood-2001-12-0350. Blood. 2002. PMID: 12091352 Free article.

3

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.

Yee KW, O'Farrell AM, Smolich BD, Cherrington JM, McMahon G, Wait CL, McGreevey LS, Griffith DJ, Heinrich MC. Yee KW, et al. Among authors: cherrington jm. Blood. 2002 Oct 15;100(8):2941-9. doi: 10.1182/blood-2002-02-0531. Blood. 2002. PMID: 12351406 Free article.

4

Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.

London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM. London CA, et al. Among authors: cherrington jm. Clin Cancer Res. 2003 Jul;9(7):2755-68. Clin Cancer Res. 2003. PMID: 12855656 Clinical Trial.

5

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. Mendel DB, et al. Among authors: cherrington jm. Clin Cancer Res. 2003 Jan;9(1):327-37. Clin Cancer Res. 2003. PMID: 12538485

6

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D. Patyna S, et al. Among authors: cherrington jm. Mol Cancer Ther. 2006 Jul;5(7):1774-82. doi: 10.1158/1535-7163.MCT-05-0333. Mol Cancer Ther. 2006. PMID: 16891463

7

Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.

Laird AD, Li G, Moss KG, Blake RA, Broome MA, Cherrington JM, Mendel DB. Laird AD, et al. Mol Cancer Ther. 2003 May;2(5):461-9. Mol Cancer Ther. 2003. PMID: 12748308

8

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.

Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB. Potapova O, et al. Among authors: cherrington jm. Mol Cancer Ther. 2006 May;5(5):1280-9. doi: 10.1158/1535-7163.MCT-03-0156. Mol Cancer Ther. 2006. PMID: 16731761

9

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.

Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT. Giles FJ, et al. Among authors: cherrington jm. Cancer. 2003 Apr 15;97(8):1920-8. doi: 10.1002/cncr.11315. Cancer. 2003. PMID: 12673719 Free article. Clinical Trial.

10

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. Abrams TJ, et al. Among authors: cherrington jm. Mol Cancer Ther. 2003 May;2(5):471-8. Mol Cancer Ther. 2003. PMID: 12748309

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters